Navigation Links
BioMarin Provides Grant to NORD to Expand PKU Patient Support Services
Date:10/24/2007

Financial Assistance Intended To Help Patients with Out of Pocket Expenses

for Medical Foods

NOVATO, Calif., Oct. 24 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) announced today that it has provided a $250,000 grant to the National Organization for Rare Disorders (NORD) to support a new financial assistance program for patients with phenylketonuria (PKU), a rare genetic metabolic disorder. Funds from this new program may be renewed based on ongoing need and are specifically directed to help PKU patients with the substantial daily cost of medical foods when not paid for by insurance or Medicaid programs. NORD is working closely with Genetic Metabolic Dietitians International (GMDI), an independent professional organization, to develop program guidelines and provide ongoing support to NORD in the administration of these funds.

"We are committed to the PKU community and believe that it is important that every patient obtains optimal therapeutic treatment," said Jean-Jacques Bienaime, Chief Executive Officer of BioMarin. "We are pleased to expand our relationship with NORD and GMDI to assist patients with out of pocket costs and help to ensure that patients in need are not limited by financial constraints."

"PKU patients must maintain strict diets and rely on costly medical foods which are not covered by most insurance companies. This can cost families thousands of dollars per year," said Abbey Meyers, President and co-founder of NORD. "This grant will enable us to enhance our services to better meet the immediate needs of PKU patients and alleviate the considerable financial burden this illness has on their families."

"Consistent with our mission to maximize the benefits of newborn screening and prevent the devastating outcomes of an untreated disease through the use of medical foods, we are pleased to work with NORD and BioMarin to help the PKU community. Together, we are dedi
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. Protein provides antioxidant protection to Neurons
2. Acupuncture provides relief
3. Micro-camera provides new breast imaging technique
4. Hormone therapy provides no heart benefit
5. MicroRNA provides new insight into birth defects
6. Drug Spironolactone Provides Renal And Cardioprotection In Diabetic Patients
7. Neurobiology Provides Answers To Block Memory-Related Drug Cravings
8. Cholesterol provides immunity against infection by certain parasites
9. John Hopkins CGHH program provides Global Health education
10. London Hospital Provides Specialized Care For Pregnant Women
11. Hope Lodges provides free stay to cancer patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2008)...ov. 21 /PRNewswire/ -- For the second year in a...McCann Healthcare Worldwide,s agency network won m...at the 22nd annual international RX Club Show. ,...ffices won a total of 59 RX Club Awards of Excelle...McCann Healthcare Worldwide agencies include Caude...
(Date:11/21/2008).... 21 Innerscope Research(TM), a re...izing in Emotional Response Measurement,announce...ll strengthen the,company,s research and developm... , The three appointments, who deliver a co...ill as Chief Financial Officer and Vice President ...
(Date:11/21/2008)...ING HARBOR, N.Y. (Nov. 21, 2008) How can moss he...lamprey immune system tell us about evolution? Ca...ith efforts to conserve rare species? What can qu...hereditary diseases? Will studies of choanoflagel...r these and other questions in biology, scientists...
(Date:11/21/2008)... Nov. 21 New inventions in compute...ty of cognitive disabilities lead fuller,lives, s...oration. Zimman,presented today at the annual Tec...a meeting organized by The National Center for Tec...t people with disabilities. , Zimman said c...
Breaking Medicine News(10 mins):Health News:McCann Healthcare Worldwide Agencies Again Win Most Awards at RX Club Show 2008 2Health News:McCann Healthcare Worldwide Agencies Again Win Most Awards at RX Club Show 2008 3Health News:McCann Healthcare Worldwide Agencies Again Win Most Awards at RX Club Show 2008 4Health News:Innerscope Research Strengthens Management Team With Three Executive Appointments 2Health News:A new world of research possibilities with 'Emerging Model Organisms' 2Health News:New Applications for Cognitive Training 2
...ostate-specific antigen (PSA) is the first indicat...ostatectomy. In a new Mayo Clinic study, the con...liable tool to distinguish which patients have pro...apy from those who are at great risk for disease r...
...ith untreated sleep apnea are more likely to die t...y//. The study followed 164 patients with heart ...those with obstructive sleep apnea (OSA) had doubl...o did not have sleep apnea. Of the 37 patients wit...
...s been found to be of immense help for patients to...y. “There’s an important use for the telephone in... activity and diet,” said Elizabeth Eakin, Ph.D., ...niversity of Queensland in Australia. Eakin and h...
...to navigate the NHS services’, UK ‘s Health Mini...signed to give patients// the choice to select the...ion on anything related to health. Says Hewitt: “...e heart of the NHS and making sure patients can ac...
Other Medicine News:Health News:Sleep Disorder Linked to Heart Failure Patient Deaths 2Health News:Sleep Disorder Linked to Heart Failure Patient Deaths 3Health News:Phone Counseling Helps Patients Improve Eating and Exercise Habits 2Health News:Phone Counseling Helps Patients Improve Eating and Exercise Habits 3Health News:NHS Online- Promise Of ‘Choices’ To Patien 2
(Date:11/19/2008)... Roche- , , MONTVALE, N.J., Nov. 19 /PRNews...asdaq: MEMY ) today announced that it has achiev...487/MEM 3454, its lead alpha-7 nicotinic receptor ...chizophrenia (CIAS). The Company has randomized 2...0 million payment from its partner Roche. Memory ...
(Date:11/18/2008)...re-USNewswire/ -- Forty-two leading U. S. scientis... forum to consider cutting-edge innovations that m...nomy from outbreaks of dangerous zoonotic diseases...g those innovations: , , , , A ...t detects highly contagious and dangerous zoonotic...
(Date:11/13/2008)...l Supplements Prior to Surgery, ARLINGTON HEIGHTS...ying,malnutrition before surgery in massive weight...icantly decrease surgical complications, accelerat...tient energy levels,according to a study in the D...y(R), the official medical journal of the American...
(Date:11/12/2008)...el, November 12 Surgeons,at the Un... that,patient-specific CTA data can be converted t...bionix US) with high face validity. The surgeons,"...operative flow,increased patient safety and effic...ve and fluoroscopy time and the amount of contrast...
Breaking Medicine Technology:Memory Pharmaceuticals Achieves Enrollment Goal for Phase 2 Study of MEM 3454 in Cognitive Impairment Associated With Schizophrenia 2Memory Pharmaceuticals Achieves Enrollment Goal for Phase 2 Study of MEM 3454 in Cognitive Impairment Associated With Schizophrenia 342 Top U.S. Scientists and Specialists Explore Cutting-Edge Innovations to Defend America From Dangerous Zoonotic Diseases 2Plastic Surgeons Warn of Malnutrition in Body Contouring Patients 2Vascular Surgeons Agree: Case Rehearsal Improves Outcomes 2Panacea Pharmaceuticals Announces the Availability of BC Detect 28SM 29 a Serum Based Diagnostic Test for Breast Cancer 1309 1Panacea Pharmaceuticals Announces the Availability of BC Detect 28SM 29 a Serum Based Diagnostic Test for Breast Cancer 1309 2Panacea Pharmaceuticals Announces the Availability of BC Detect 28SM 29 a Serum Based Diagnostic Test for Breast Cancer 1309 3Panacea Pharmaceuticals Announces the Availability of BC Detect 28SM 29 a Serum Based Diagnostic Test for Breast Cancer 1309 4Organons Asenapine Further Demonstrates Efficacy in Reducing Mania Symptoms for the Treatment of Bipolar I Disorder 1304 1Organons Asenapine Further Demonstrates Efficacy in Reducing Mania Symptoms for the Treatment of Bipolar I Disorder 1304 2Organons Asenapine Further Demonstrates Efficacy in Reducing Mania Symptoms for the Treatment of Bipolar I Disorder 1304 3Organons Asenapine Further Demonstrates Efficacy in Reducing Mania Symptoms for the Treatment of Bipolar I Disorder 1304 4Organons Asenapine Further Demonstrates Efficacy in Reducing Mania Symptoms for the Treatment of Bipolar I Disorder 1304 5Organons Asenapine Further Demonstrates Efficacy in Reducing Mania Symptoms for the Treatment of Bipolar I Disorder 1304 6Mirixa Debuts RxFYI a Free Pharmacy Published Health eNewsletter Building Patient Loyalty and Generating Revenue 3893 1Mirixa Debuts RxFYI a Free Pharmacy Published Health eNewsletter Building Patient Loyalty and Generating Revenue 3893 2ImClone and Bristol Myers Squibb Announce Joint Agreement With Merck KGaA to Co Develop and Co Commercialize ERBITUX 28R 29 in Japan 3889 1ImClone and Bristol Myers Squibb Announce Joint Agreement With Merck KGaA to Co Develop and Co Commercialize ERBITUX 28R 29 in Japan 3889 2ImClone and Bristol Myers Squibb Announce Joint Agreement With Merck KGaA to Co Develop and Co Commercialize ERBITUX 28R 29 in Japan 3889 3ImClone and Bristol Myers Squibb Announce Joint Agreement With Merck KGaA to Co Develop and Co Commercialize ERBITUX 28R 29 in Japan 3889 4ImClone and Bristol Myers Squibb Announce Joint Agreement With Merck KGaA to Co Develop and Co Commercialize ERBITUX 28R 29 in Japan 3889 5ImClone and Bristol Myers Squibb Announce Joint Agreement With Merck KGaA to Co Develop and Co Commercialize ERBITUX 28R 29 in Japan 3889 6ImClone and Bristol Myers Squibb Announce Joint Agreement With Merck KGaA to Co Develop and Co Commercialize ERBITUX 28R 29 in Japan 3889 7
...SINESS WIRE)--Jun 5, 2007 - First-in-human results...mClone Systems,Incorporated (NASDAQ: IMCL) and tar... receptor), were presented at the annual,meeting o...cago.,The IGF-IR is expressed on the cell surface ...ead to tumor cell growth and,proliferation, and in...
...ss.--(BUSINESS WIRE)--Jun 5, 2007 - Elixir,Pharmac...ta,confirming ghrelin antagonism as a potential me...ight and managing blood glucose. The,data were pre...crine Society,s 89th Annual Meeting, being held in...ment of drugs to treat and,prevent metabolic disea...
Other Medicine Technology:Phase I Results for ImClone Pipeline Anti-IGF-1R Monoclonal,Antibody IMC-A12 Presented at ASCO 2Phase I Results for ImClone Pipeline Anti-IGF-1R Monoclonal,Antibody IMC-A12 Presented at ASCO 3Elixir Pharmaceuticals Presents Additional Preclinical Data,Demonstrating the Potential of Ghrelin Antagonism to Regulate,Metabolism, Body Weight and Glycemic Control 2Elixir Pharmaceuticals Presents Additional Preclinical Data,Demonstrating the Potential of Ghrelin Antagonism to Regulate,Metabolism, Body Weight and Glycemic Control 3Elixir Pharmaceuticals Presents Additional Preclinical Data,Demonstrating the Potential of Ghrelin Antagonism to Regulate,Metabolism, Body Weight and Glycemic Control 4
...ghput immunoassay system built around the many pos...important addition of Logic Driven Incubation (LDI...for optimal performance with the fastest possible ...ys such as the cardiac biomarkers and HCG to be ru...
For The Detection Of Serum C-Peptide Levels.,Clinical Uses Of C-Peptide Measurement:, Evaluating patients with fasting hypoglycemia , Assisting in the classification of diabetes mellitus , D
Measles IgG ELISA test system is designed for the qualitative detection of IgG antibodies to Measles (Rubeola) virus in human serum, and is for in vitro diagnostic use.
Inquire
Medicine Products: